variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Study ID
- NCT07463976
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Chronic Lymphocytic Leukemia
- Haematological Malignancy
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study will use surveys within primary and secondary care to explore referral patterns and healthcare professional (HCP) decision-making and advice for haematological malignancies, identify inequalities, and establish best practice for CLL referrals and specialist support. The project will allow us to understand and 'map' variations in practice across the West Midlands region with regard to referrals for CLL from primary care physicians to haematology services in secondary care. Specific objectives are to: 1. Identify service variations by using surveys to assess differences in CLL service provision across primary and secondary care in the West Midlands 2. Investigate service variations by describing the key characteristics of responding primary care practices (practice size, number of GPs, Integrated Care Board (ICB) locality, deprivation quartile) 3. Propose strategies to improve equity that will enhanced patient outcomes and reduce inequalities in care for CLL patients, aiming to ensure consistent standards for referral and management across different care settings.
Key Dates
- First listed
- Mar 11, 2026
- Start date
- Jul 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 130 participants (estimated)
Primary Outcome Measure
Identify service variations [ Time Frame: 12 months ]
Central Contacts
- Jen Edgecombe01902 695065
- Lorraine Jacques
Find similar trials
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Orange, California
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas